SCHEMBL4905018

SCHEMBL4905018

O=C1c2ccccc2C(=O)N1CCOc1ccc(-c2ccccc2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.74
NPSR1 Q6W5P4 1/20 0.74
RAB9A P51151 9/20 0.72
NPC1 O15118 4/20 0.72
SMN1; SMN2 Q16637 2/20 0.69
MAPT P10636 1/20 0.69
TDP1 Q9NUW8 2/20 0.58
KMT2A Q03164 1/20 0.58
MMP2 P08253 2/20 0.56
MMP3 P08254 2/20 0.56
MMP9 P14780 2/20 0.56
MMP13 P45452 2/20 0.56
MMP1 P03956 1/20 0.56
POLB P06746 1/20 0.56
APEX1 P27695 1/20 0.56
HSD17B10 Q99714 1/20 0.56
TSHR P16473 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
LTA4H P09960 1/20 0.54
ATM Q13315 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29237869 0.97 HPGD (0.79) HPGDNPSR1RAB9ANPC1SMN1; SMN2
SCHEMBL31030951 0.97 HPGD (0.79) HPGDNPSR1RAB9ANPC1SMN1; SMN2
SCHEMBL10674350 0.92 RAB9A (0.82) HPGDNPSR1RAB9ANPC1SMN1; SMN2
SCHEMBL8483472 0.91 RAB9A (0.74) HPGDNPSR1RAB9ANPC1SMN1; SMN2
SCHEMBL1578469 0.90 RAB9A (0.83) HPGDNPSR1RAB9ANPC1SMN1; SMN2
SCHEMBL10683824 0.89 RAB9A (0.72) HPGDNPSR1RAB9ANPC1SMN1; SMN2
SCHEMBL10680795 0.89 RAB9A (0.72) HPGDNPSR1RAB9ANPC1SMN1; SMN2
SCHEMBL10682756 0.89 RAB9A (0.72) HPGDNPSR1RAB9ANPC1SMN1; SMN2
SCHEMBL10683303 0.89 RAB9A (0.72) HPGDNPSR1RAB9ANPC1SMN1; SMN2
SCHEMBL10675533 0.89 RAB9A (0.72) HPGDNPSR1RAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER INC. 2008-04-17 US disclosed
US-20060229363-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds HAMANAKA ERNEST S 2006-10-12 US disclosed
US-20050288340-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229363-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PPARA, PPARG, PPARD HPGD 696/4885NPSR1 773/4885RAB9A 2581/4885
US-20050288340-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PPARA, PPARG, PPARD HPGD 724/4885NPSR1 735/4885RAB9A 2271/4885
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PPARA, PPARG, PPARD HPGD 724/4885NPSR1 735/4885RAB9A 2271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.